Subdiuretic dose of furosemide enhances albuterol effects in asthmatic mice rather than bumetanide

Main Article Content

H. Murad
T. Ghabrah
M. Rafeeq
S. Ali

Keywords

Asthma, Albuterol, Furosemide, Bumetanide, Inhalation, Diuresis

Abstract

Background: One of the loop diuretics, furosemide, was found useful in bronchial asthma. It enhanced anti-asthmatic effects of albuterol. The underlying mechanism is still unclear.


Objective: This study was planned to investigate whether the enhancing effect of furosemide for albuterol in ovalbumin-induced asthmatic BALB/c mice is diuretic-related or not.


Methods: Two sets of experiments were performed. In the first, effects of inhaled subdiuretic doses of furosemide and bumetanide (another loop diuretic) were compared. Treatments (mg/mL) were given as 15 minute-inhalation before final ovalbumin provocation as follows: albuterol (2.5), furosemide (0.08), bumetanide (0.005), (albuterol + furosemide, 2.5 + 0.08), and (albuterol + bumetanide, 2.5 + 0.005). Airway hyperreactivity (AHR) to inhaled methacholine, levels of IL-6, TNF-, and differential white blood cells in bronchoalveolar lavage fluid (BALF), and lung histopathology were evaluated. In the second set, effects of oral diuretic doses (mg/kg) of furosemide (10) and bumetanide (0.25) were given before final ovalbumin provocation. Urine volume and asthma parameters were measured.


Results: Ovalbumin-asthmatic mice showed significant increases in AHR, levels of IL-6, TNF-α, and inflammatory cells in BALF, and lung inflammatory cell infiltration. Inhaled furosemide significantly decreased these changes while inhaled bumetanide failed. Albuterol and albuterol + bumetanide significantly decreased these changes more than furosemide while albuterol + furosemide produced the most significant decreases. Both oral furosemide and bumetanide exerted equivalent diuretic effects but failed to improve asthma.


Conclusions: Inhaled subdiuretic dose of furosemide enhanced effects of albuterol more in ovalbumin-asthmatic mice rather than bumetanide, while oral diuretic doses of both drugs failed to improve asthma, indicating that this enhancing effect is not diuretic-related.

Abstract 52 | PDF Downloads 35

References

1. Sheikh A, Steiner MF, Cezard G, Bansal N, Fischbacher C, Simpson CR, et al. Ethnic variations in asthma hospital admission, readmission and death: a retrospective, national cohort study of 4.62 million people in Scotland. BMC Med. 2016;14:3.

2. Bateman ED, Hurd S, Barnes P, Bousquet J, Drazen J, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143-78.

3. Silva D, Jacinto T. Inhaled 2-agonists in asthma management: an evolving story. Breathe. 2016;12:375.

4. Tilley SL. Methylxanthines in asthma. Handb Exp Pharmacol. 2011:439-56, 200.

5. Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2 agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;24:CD007949.

6. Sindi A, Todd DC, Nair P. Antiinflammatory effects of long-acting 2-agonists in patients with asthma: a systematic review and metaanalysis. Chest. 2009;136:145-54.

7. Erdem SB, Nacaroglu HT, Karkiner CSU, Gunay I, Can D. Side effects of leukotriene receptor antagonists in asthmatic children. Iran J Pediatr. 2015;25.

8. Boyce JA. The role of mast cells in asthma. Prostaglandins Leukot Essent Fatty Acids. 2003;69(2-3):195-205.

9. Inokuchi R, Aoki A, Aoki Y, Yahagi N. Effectiveness of inhaled furosemide for acute asthma exacerbation: a meta-analysis. Crit Care. 2014;18:621.

10. Boyden JY, Connor SR, Otolorin L, Nathan SD, Fine PG, Davis MS, et al. Nebulized medications for the treatment of dyspnea: a literature review. J Aerosol Med Pulm Drug Deliv. 2015;28:1-19.

11. Iwamoto LM, Nakamura KT, Wada RK. Immunolocalization of a Na-K-2Cl cotransporter in human tracheobronchial smooth muscle. J Appl Physiol. 2003;94:1596-601.

12. Barnes P. Diuretics and asthma. Thorax. 1993;48:195.

13. Nappi JM. A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide. Pharm Pract (Granada). 2013;11:44-50.

14. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen G, Irvin C, et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med. 1997;156:766-75.

15. Franova S, Kazimierova I, Pappova L, Joskova M, Plank L, Sutovska M. Bronchodilatory, antitussive and anti-inflammatory effect of morin in the setting of experimentally induced allergic asthma. J Pharm Pharmacol. 2016;68:1064-72.

16. Kazimierová I, Pappová L, ˇSutovská M, Franová ˇ S. The effect of short-term and long-term application of fisetin on experimentally induced airway hyperreactivity. Acta Fac Pharm Univ Comen. 2017:10-1.

17. Paget G, Barnes J. Toxicity tests. Evaluation of drug activities. Pharmacometrics. 1964;1:135-65.

18. Oriaifo S, Omogbai E. Comparative effects of imipramine, sertraline, nifedipine, furosemide and bumetanide on ingestive behaviour in mice. Afr J Biotechnol. 2011;10: 18022-6.

19. Chopda GR, Vemuri VK, Sharma R, Thakur GA, Makriyannis A, Paronis CA. Diuretic effects of cannabinoid agonists in mice. Eur J Pharmacol. 2013;721:64-9.

20. Zhang W, Fievez L, Cheu E, Bureau F, Rong W, Zhang F, et al. Anti-inflammatory effects of formoterol and ipratropium bromide against acute cadmium-induced pulmonary inflammation in rats. Eur J Pharmacol. 2010;628:171-8.

21. Rudmann DG, Moore MW, Tepper JS, Aldrich MC, Pfeiffer JW, Hogenesch H, et al. Modulation of allergic inflammation in mice deficient in TNF receptors. Am J Physiol Lung Cell Mol Physiol. 2000;279:L1047-57.

22. Jung CH, Lee JY, Cho CH, Kim CJ. Anti-asthmatic action of quercetin and rutin in conscious guinea-pigs challenged with aerosolized ovalbumin. Arch Pharm Res. 2007;30: 1599.

23. Kumar R, Gaur S, Vatsa H. The role of inhaled frusemide in management of bronchial asthma. Indian J Allergy Asthma Immunol. 2003;17:5-8.

24. Masoumi K, Forouzan A, Haddadzadeh Shoushtari M, Porozan S, Feli M, Fallah Bagher Sheidaee M, et al. The efficacy of nebulized furosemide and salbutamol compared with salbutamol alone in reactive airway disease: a double-blind randomized, clinical trial. Emerg Med Int. 2014, 2014.

25. Wang S, Xiang YY, Ellis R, Wattie J, Feng M, Inman M, et al. Effects of furosemide on allergic asthmatic responses in mice. Clin Exp Allergy. 2011;41:1456-67.

26. Sahni J, Phelps SJ. Nebulized furosemide in the treatment of bronchopulmonary dysplasia in preterm infants. J Pediatr Pharmacol Ther. 2011;16:14-22.

27. Meehan S, Bassett P, Lonjaret J-G, Hempleman S, Sheridan K. KCC and NKCC activity affect spike frequency adaptation in CO2-sensitive avian intrapulmonary chemoreceptors (1092.3). FASEB J. 2014;28 Suppl, 1092.3.

28. Frlic O, Seliˇskar A, Domanjko Petriˇc A, Blagus R, Heigenhauser G, Vengust M. Pulmonary circulation transvascular fluid fluxes do not change during general anesthesia in dogs. Front Physiol. 2018;9:124.

29. Newton PJ, Davidson PM, Macdonald P, Ollerton R, Krum H. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage. 2008;36:424-41.

30. Prandota J. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. Am J Ther. 2002;9:317-28.

31. Gauvreau GM, El-Gammal AI, O’Byrne PM. Allergen-induced airway responses. Eur Respir J. 2015;46:819-31.

32. Bhure UN, Bhure SU, Bhatt BM, Mistry S, Pednekar S, Chari V, et al. Lung epithelial permeability and inhaled furosemide: added dimensions in asthmatics. Ann Nucl Med. 2009;23:549-57.

33. Nuho˘glu C¸, Kilic MY, Ceran Ö. Effectiveness of nebulized furosemide added to nebulized salbutamol in children with acute asthma. Allergol Immunopathol. 2006;34:54-8.

34. Alshehri M, Almegamesi T, Alfrayh A. Efficacy of nebulized furosemide in children with moderate attack of asthma. West Afr J Med. 2005;24:246-51.

35. Avital A, Godfrey S, Springer C. Exercise, methacholine, and adenosine 5′-monophosphate challenges in children with asthma: relation to severity of the disease. Pediatr Pulmonol. 2000;30:207-14.

36. Iwamoto LM, Gries DM, Nakamura KT. Loop diuretics and in vitro relaxation of human fetal and newborn mouse airways. Pediatr Res. 2001;50:273-6.

37. Chambers LA, Rollins BM, Tarran R. Liquid movement across the surface epithelium of large airways. Respir Physiol Neurobiol. 2007;159:256-70.

38. O’connor BJ, Chung KF, Chen-Worsdell YM, Fuller RW, Barnes PJ. Effect of inhaled furosemide and bumetanide on adenosine 5′-monophosphate-and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects. Am Rev Respir Dis. 1991;143:1329---33.

39. Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015;169:323-33.

40. Bialasiewicz P, Wlodarczyk A, Dudkiewicz B, Nowak D. Inhibitory effect of furosemide on activation of human peripheral blood polymorphonuclear leukocytes stimulated with n-formyl-methionyl-leucyl-phenylalanine. Int Immunopharmacol. 2004;4:819-31.